Literature DB >> 26438008

Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis.

Tatiana Hildebrand1, Nadine Pannicke2, Alexander Dechene3, Daniel N Gotthardt4, Gabriele Kirchner5, Florian P Reiter6, Martina Sterneck2,7, Kerstin Herzer8, Henrike Lenzen1, Christian Rupp4, Hannelore Barg-Hock9, Philipp de Leuw10, Andreas Teufel5,11, Vincent Zimmer12, Frank Lammert12, Christoph Sarrazin10, Ulrich Spengler13, Christian Rust6, Michael P Manns1, Christian P Strassburg1,13, Christoph Schramm2, Tobias J Weismüller1,13.   

Abstract

Liver transplantation (LT) is the only definitive treatment for patients with end-stage liver disease due to primary sclerosing cholangitis (PSC), but a high rate of biliary strictures (BSs) and of recurrent primary sclerosing cholangitis (recPSC) has been reported. In this multicenter study, we analyzed a large patient cohort with a long follow-up in order to evaluate the incidence of BS and recPSC, to assess the impact on survival after LT, and to identify risk factors. We collected clinical, surgical, and laboratory data and records on inflammatory bowel disease (IBD), immunosuppression, recipient and graft outcome, and biliary complications (based on cholangiography and histology) of all patients who underwent LT for PSC in 10 German transplant centers between January 1990 and December 2006; 335 patients (68.4% men; mean age, 38.9 years; 73.5% with IBD) underwent transplantation 8.8 years after PSC diagnosis with follow-up for 98.8 months. The 1-, 5-, and 10-year recipient and graft survival was 90.7%, 84.8%, 79.4% and 79.1%, 69.0%, 62.4%, respectively. BS was diagnosed in 36.1% after a mean time of 3.9 years, and recPSC was diagnosed in 20.3% after 4.6 years. Both entities had a significant impact on longterm graft and recipient survival. Independent risk factors for BS were donor age, ulcerative colitis, chronic ductopenic rejection, bilirubin, and international normalized ratio (INR) at LT. Independent risk factors for recPSC were donor age, IBD, and INR at LT. These variables were able to categorize patients into risk groups for BS and recPSC. In conclusion, BS and recPSC affect longterm graft and patient survival after LT for PSC. Donor age, IBD, and INR at LT are independent risk factors for BS and recPSC and allow for risk estimation depending on the recipient-donor constellation.
© 2015 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2016        PMID: 26438008     DOI: 10.1002/lt.24350

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  26 in total

1.  Safety of vedolizumab in liver transplant recipients: A systematic review.

Authors:  Marco Spadaccini; Alessio Aghemo; Flavio Caprioli; Ana Lleo; Federica Invernizzi; Silvio Danese; Maria F Donato
Journal:  United European Gastroenterol J       Date:  2019-06-20       Impact factor: 4.623

Review 2.  Guideline review: British Society of Gastroenterology/UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis.

Authors:  Alberto Nicoletti; James B Maurice; Douglas Thorburn
Journal:  Frontline Gastroenterol       Date:  2020-03-02

Review 3.  Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients.

Authors:  Bettina M Buchholz; Panagis M Lykoudis; Reena Ravikumar; Joerg M Pollok; Giuseppe K Fusai
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 4.  [Primary sclerosing cholangitis : Current diagnostics and treatment].

Authors:  T Liwinski; C Schramm
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

5.  Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis.

Authors:  Jacqueline B Henson; Yuval A Patel; Julius M Wilder; Jiayin Zheng; Shein-Chung Chow; Lindsay Y King; Andrew J Muir
Journal:  Dig Dis Sci       Date:  2017-04-08       Impact factor: 3.199

6.  Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver.

Authors:  Aldo J Montano-Loza; Jessica R Allegretti; Angela Cheung; Maryam Ebadi; David Jones; Nanda Kerkar; Cynthia Levy; Sumera Rizvi; John M Vierling; Fernando Alvarez; Wayne Bai; Susan Gilmour; Aliya Gulamhusein; Orlee Guttman; Bettina E Hansen; Sonya MacParland; Andrew Mason; Fernanda Onofrio; Pere Santamaria; Ashley Stueck; Mark Swain; Catherine Vincent; Amanda Ricciuto; Gideon Hirschfield
Journal:  Can Liver J       Date:  2021-11-11

Review 7.  Primary sclerosing cholangitis: review for radiologists.

Authors:  Matthew A Morgan; Rachita Khot; Karthik M Sundaram; Daniel R Ludwig; Rashmi T Nair; Pardeep K Mittal; Dhakshina M Ganeshan; Sudhakar K Venkatesh
Journal:  Abdom Radiol (NY)       Date:  2022-09-05

Review 8.  Post-Transplant Disease Recurrence in Pediatric PSC.

Authors:  Nisreen Soufi; Fateh Bazerbachi; Mark Deneau
Journal:  Curr Gastroenterol Rep       Date:  2018-08-06

Review 9.  The endoscopist and malignant and non-malignant biliary obstruction.

Authors:  S P Pereira; G Goodchild; G J M Webster
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-09-18       Impact factor: 5.187

10.  [Surgical treatment of primary sclerosing cholangitis : Experiences from 30 years in a single center cohort with 173 consecutive patients].

Authors:  Vittorio Branchi; Tobias J Weismüller; Taotao Zhou; Jonas Henn; Alexander Semaan; Tim R Glowka; Maria Gonzalez-Carmona; Christian Strassburg; Jörg C Kalff; Steffen Manekeller; Hanno Matthaei
Journal:  Chirurg       Date:  2021-02       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.